JP2020516655A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516655A5 JP2020516655A5 JP2019555941A JP2019555941A JP2020516655A5 JP 2020516655 A5 JP2020516655 A5 JP 2020516655A5 JP 2019555941 A JP2019555941 A JP 2019555941A JP 2019555941 A JP2019555941 A JP 2019555941A JP 2020516655 A5 JP2020516655 A5 JP 2020516655A5
- Authority
- JP
- Japan
- Prior art keywords
- amhrii
- binding agent
- agent according
- seq
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305446.1 | 2017-04-14 | ||
| EP17305446 | 2017-04-14 | ||
| PCT/EP2018/059553 WO2018189381A1 (en) | 2017-04-14 | 2018-04-13 | Amhrii-binding compounds for preventing or treating lung cancers |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020516655A JP2020516655A (ja) | 2020-06-11 |
| JP2020516655A5 true JP2020516655A5 (https=) | 2021-05-20 |
| JP7289420B2 JP7289420B2 (ja) | 2023-06-12 |
| JP7289420B6 JP7289420B6 (ja) | 2023-06-30 |
Family
ID=58672546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555941A Active JP7289420B6 (ja) | 2017-04-14 | 2018-04-13 | 肺癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230227566A1 (https=) |
| EP (1) | EP3609919A1 (https=) |
| JP (1) | JP7289420B6 (https=) |
| KR (2) | KR102759138B1 (https=) |
| CN (1) | CN110944665B (https=) |
| BR (1) | BR112019021495A8 (https=) |
| CA (1) | CA3058541A1 (https=) |
| MX (2) | MX2019012136A (https=) |
| WO (1) | WO2018189381A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200014276A (ko) * | 2017-04-14 | 2020-02-10 | 가마맵스 파마 | 암을 예방 또는 치료하기 위한 amhrii-결합 화합물 |
| KR20210122814A (ko) * | 2019-02-01 | 2021-10-12 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 조작된 유전자 발현을 조절하기 위한 미세환경 센서 |
| CA3139956A1 (en) * | 2019-05-31 | 2020-12-03 | Laura DETTI | Anti-mullerian hormone receptor binding peptides |
| WO2021058744A1 (en) * | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of müllerian inhibiting substance inhibitors for treating cancer |
| WO2021155295A1 (en) * | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
| KR20240149925A (ko) * | 2022-02-16 | 2024-10-15 | 더 클리브랜드 클리닉 파운데이션 | Amhr2-ed 암 백신 제제 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| WO2005005615A2 (en) * | 2003-07-08 | 2005-01-20 | Fox Chase Cancer Center | Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer |
| EP1918304A1 (en) * | 2006-11-02 | 2008-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II) |
| WO2008116161A2 (en) * | 2007-03-22 | 2008-09-25 | The General Hospital Corporation | Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states |
| FR2959994B1 (fr) | 2010-05-12 | 2012-08-24 | Lfb Biotechnologies | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
| WO2012166712A1 (en) * | 2011-05-27 | 2012-12-06 | Fox Chase Cancer Center | Rationally-designed anti-mullerian inhibiting substance type ii receptor antibodies |
| FR2984750B1 (fr) * | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
| US10509035B2 (en) * | 2015-08-07 | 2019-12-17 | Gamamabs Pharma Sa | Antibodies, antibody drug conjugates and methods of use |
| WO2018148649A1 (en) * | 2017-02-10 | 2018-08-16 | The Institute For Cancer Research D/B/A | Chimera of bone morphogenic protein 2 and the müllerian-inhibiting substance type ii receptor binding region of mullerian-inhibiting substance |
| KR20200014276A (ko) | 2017-04-14 | 2020-02-10 | 가마맵스 파마 | 암을 예방 또는 치료하기 위한 amhrii-결합 화합물 |
-
2018
- 2018-04-13 US US16/605,053 patent/US20230227566A1/en not_active Abandoned
- 2018-04-13 JP JP2019555941A patent/JP7289420B6/ja active Active
- 2018-04-13 CA CA3058541A patent/CA3058541A1/en active Pending
- 2018-04-13 MX MX2019012136A patent/MX2019012136A/es unknown
- 2018-04-13 KR KR1020197033360A patent/KR102759138B1/ko active Active
- 2018-04-13 BR BR112019021495A patent/BR112019021495A8/pt unknown
- 2018-04-13 KR KR1020257001888A patent/KR20250017758A/ko active Pending
- 2018-04-13 CN CN201880040211.4A patent/CN110944665B/zh not_active Expired - Fee Related
- 2018-04-13 WO PCT/EP2018/059553 patent/WO2018189381A1/en not_active Ceased
- 2018-04-13 EP EP18718420.5A patent/EP3609919A1/en not_active Withdrawn
-
2019
- 2019-10-09 MX MX2024003228A patent/MX2024003228A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516655A5 (https=) | ||
| Wynn et al. | Anti-HER2 therapy in metastatic breast cancer: many choices and future directions | |
| AU2016244333B2 (en) | DLL3 modulators and methods of use | |
| ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| EP4335931A3 (en) | Therapeutic and diagnostic methods for cancer | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP2018508475A5 (https=) | ||
| JP2015506944A5 (https=) | ||
| KR20190071677A (ko) | Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화 | |
| CN118834840A (zh) | 嵌合痘病毒组合物及其用途 | |
| González-Arenas et al. | Progesterone-induced blocking factor is hormonally regulated in human astrocytoma cells, and increases their growth through the IL-4R/JAK1/STAT6 pathway | |
| JP2019510739A5 (https=) | ||
| RU2016141385A (ru) | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf | |
| JP2018530331A5 (https=) | ||
| JP2015508063A5 (https=) | ||
| Sanchorawala et al. | Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study | |
| Renga et al. | The HIV matrix protein p17 promotes the activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2 | |
| US20230147832A1 (en) | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer | |
| Borthwick et al. | Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1 | |
| US20160074428A1 (en) | Compositions and methods for the treatment of human immunodeficiency virus infection | |
| JP2021531245A5 (https=) | ||
| Agaugue et al. | The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer | |
| US20250186520A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer | |
| JP2019531254A5 (https=) | ||
| CN116940378A (zh) | 神经内分泌癌的治疗 |